Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis
Circulation · 2023
DOI: 10.1161/circulationaha.122.060757 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Circulation, 2023. Verfasst von Gerasimos Filippatos und 14 weiteren Autor:innen. Beteiligte Einrichtung: National and Kapodistrian University of Athens Medical School, Athens University Hospital Attikon, Athens, Greece (G.F., D.F.). Hauptthemen laut MEDLINE: Iron Deficiencies, Anemia, Heart Failure. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
Iron deficiency, with or without anemia, is an adverse prognostic factor in heart failure (HF). In AFFIRM-AHF (a randomized, double-blind placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalizations and mortality in iron-deficient subjects admitted for acute heart failure), intravenous ferric carboxymaltose (FCM), although having no significant effect on the primary end point, reduced the risk of HF hospitalization (hHF) and improved quality of life versus placebo in iron-deficient patients stabilized after an acute HF (AHF) episode. These prespecified AFFIRM-AHF subanalyses explored the association between hemoglobin levels and FCM treatment effects.
Methods
AFFIRM-AHF was a multicenter, double-blind, randomized, placebo-controlled trial of FCM in hospitalized AHF patients with iron deficiency. Patients were stratified by baseline hemoglobin level (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National and Kapodistrian University of Athens Medical School, Athens University Hospital Attikon, Athens, Greece (G.F., D.F.).
- Institute of Heart Diseases, Wroclaw Medical University; and Institute of Heart Diseases, University Hospital, Wroclaw, Poland (P.P., E.A.J.).
- Department of Cardiology and Berlin Institute of Health Center for Regenerative Therapies, German Centre for Cardiovascular Research Partner Site Berlin, Charité Universitätsmedizin Berlin, Germany (S.D.A.).
- University of Mississippi Medical Center, Jackson (J.B.).
- Vifor Pharma Ltd, Glattbrugg, Switzerland (V.F., S.W.).
- Department of Clinical Research, SOCAR Research SA, Nyon, Switzerland (B-A.K.).
ORCID-Profile: Gerasimos Filippatos, Piotr Ponikowski, Dimitrios Farmakis, Stefan D Anker, Javed Butler, Marco Metra, Peter van der Meer
Zitieren
APA
Filippatos, G., Ponikowski, P., Farmakis, D., Anker, S. D., Butler, J., Fabien, V., Kirwan, B. A., Macdougall, I. C., Metra, M., Rosano, G., Ruschitzka, F., van der Meer, P., Wächter, S., Jankowska, E. A., & AFFIRM-AHF Investigators (2023). Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis. Circulation. https://doi.org/10.1161/circulationaha.122.060757
Vancouver
Filippatos G, Ponikowski P, Farmakis D, Anker SD, Butler J, Fabien V, et al. Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis. Circulation. 2023. doi:10.1161/circulationaha.122.060757
BibTeX
@article{Filippatos2023,
author = {Filippatos, Gerasimos and Ponikowski, Piotr and Farmakis, Dimitrios and Anker, Stefan D and Butler, Javed and Fabien, Vincent and Kirwan, Bridget-Anne and Macdougall, Iain C and Metra, Marco and Rosano, Giuseppe and Ruschitzka, Frank and van der Meer, Peter and Wächter, Sandra and Jankowska, Ewa A and AFFIRM-AHF Investigators, AFFIRM-AHF Investigators},
title = {Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis},
journal = {Circulation},
year = {2023},
doi = {10.1161/circulationaha.122.060757}
}
EUVIMED